Heramed Limited (ASX: $HMD) has requested the immediate suspension of its securities under Listing Rule 17.2. The suspension is in relation to an upcoming announcement regarding a material new contract, and the company expects to make this announcement before the commencement of normal trading on Wednesday, 28 February 2024.
The Company requests the suspension to manage its continuous disclosure obligations and to ensure that the market is informed about the upcoming announcement regarding the material new contract. We are not aware of any reason why the voluntary suspension should not be granted or any other information necessary to inform the market about the suspension.
Heramed Limited (ASX: $HMD) has voluntarily requested the suspension of its securities in anticipation of a significant announcement related to a material new contract. The company aims to manage its continuous disclosure obligations and plans to release the announcement before the commencement of normal trading on Wednesday, 28 February 2024. HeraMED is committed to ensuring that the market is informed about the upcoming announcement and is confident in the decision to request the voluntary suspension.